Vanguard Real Estate Index Fund ETF vs Viatris Inc — how do they compare? Vanguard Real Estate Index Fund ETF trades at $90.65 (market cap $70.80B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Vanguard Real Estate Index Fund ETF is far larger — about 3.5× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Vanguard Real Estate Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Real Estate Index Fund ETF for 113 Days and Viatris Inc for 57 Days on average.
| VNQ | VTRS | |
|---|---|---|
Market Cap | $70.80B | $20.03B |
Volume | 6,073,580 | 14,109,977 |
52-Week High | $100.95 | $18.27 |
52-Week Low | $87.00 | $9.74 |
Typical Hold Time | 113 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
VNQ trades at $89.35, up 0.74% today, but faces bearish technical signals with moving averages indicating selling pressure. The ETF has declined nearly 10% recently amid rising Treasury yields and Fed rate hikes, eroding its income appeal versus safer alternatives. Recent institutional buying by State Street Corp and Envestnet suggests some see value at current levels, while news highlights sector headwinds from interest rate sensitivity and oversupply concerns in certain real estate segments.
Outlook remains challenged by rising rates compressing REIT valuations, though contrarian investors see opportunity in discounted sector exposure. Key risks include prolonged high interest rates, economic slowdown impacting property demand, and competition from Treasury yields. The dividend yield advantage has narrowed significantly, requiring careful assessment of total return potential versus rate-sensitive alternatives.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →